Refine by
Applications
- Medical cannabis solutions for regulatory pathway sector
- Medical cannabis solutions for mental health costs sector
- Medical solutions for MiniTC and mini-stem system sector
- Colovac - Flexible Endoluminal Bypass Sheath for Patients
- The mat (t) isse bioprothesis: a bio-resorbable tec (tissue engineering chamber)
- Software Solutions for Deep Mutational Scanning & Selection
- Software Solutions for COVID-19
Preclinical Studies Equipment & Supplies
279 equipment items found
Manufactured by:Xstrahl based inNorcross, GEORGIA (US) (USA)
The Small Animal Radiation Research Platform (SARRP) by Xstrahl is a cutting-edge system designed for preclinical radiation research. SARRP is notable for its ability to replicate modern radiation therapy techniques within a laboratory setting, offering researchers the tools to conduct precise, clinically relevant studies. It includes an integrated Motorized ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, CytomX has decided to ...
Manufactured by:Elpiscience based inShanghai, CHINA
We designed ES005 to block LAG3 ligands, including MHC class II and FGL1. Through unique epitope binding, ES005 is able to recognize human LAG3 with high affinity. In preclinical studies, ES005 inhibited tumor growth both as a monotherapy and in combination with a PD-1 ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv used by traditional Chimeric Antigen Receptor (CAR) T cells. We believe this DAR has been demonstrated in preclinical studies greater specificity, stability and potency. ...
by:Harvard Apparatus Regenerative Technology, Inc. formely known as Biostage, Inc. based inHolliston, MASSACHUSETTS (USA)
Following extensive research and development, Biostage has evolved its technology to optimize the interaction of mesenchymal stem cells seeded on a biocompatible scaffold. Preclinical studies suggest that, once implanted, the scaffold seeded with the patient’s own cells signals the stem cell niche to guide the regeneration of a biological ...
by:Genmab A/S based inCopenhagen V, DENMARK
B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-CD3xB7H4 was shown to induce T-cell mediated cytotoxicity of B7H4-positive tumor ...
Manufactured by:Galatea Surgical, Inc. based inLexington, MASSACHUSETTS (USA)
A lightweight, low-profile P4HB scaffold, designed for anatomical compliance, to provide predictable, restorative strength. Soft Meets Strength: In preclinical studies, GalaFLEX LITE showed rapid tissue regeneration, resulting in a new tissue plane twice the strength of the native tissue. GalaFLEX LITE retains strength, supporting and reinforcing the surgical ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding ...
Manufactured by:Altis Biosystems based inDurham, NORTH CAROLINA (USA)
The high throughput platform supports quick screening of thousands of candidates and fosters efficient development through reduced timelines and costs. Focus applications include preclinical studies for compound screening, investigating the effects of diseases, and microbiome research. ...
Manufactured by:MR Solutions based inGuildford, UNITED KINGDOM
This device is particularly suitable for small animal imaging, providing researchers with robust data for advanced analysis in preclinical ...
Manufactured by:Aptevo Therapeutics based inSeattle, WASHINGTON (USA)
Demonstrated ability to produce monospecific and bispecific drug candidates; Leverages IgG1 Fc to form homodimeric bispecific molecules; IgG1-derived Fc can be mutated to ablate effector functions antibody-dependent cellcytotoxicity (ADCC) and complementdependent cytotoxicity (CDC), while maintaining original stability and half-life (confirmed by cell binding, cell function, SPRbased measurements ...
Manufactured by:FUJIFILM VisualSonics, Inc. based inToronto, ONTARIO (CANADA)
The Vevo® 3100 LT Imaging System is FUJIFILM VisualSonics’ entry-level micro-ultrasound product. It is perfectly suited for performing basic preclinical studies while meeting both your research and budgetary needs. The Vevo 3100 LT offers real-time, in vivo physiological information that contributes to understanding biological functions and so much ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures. In preclinical studies, we have observed that the removal of CD33 provided robust protection of these healthy donor HSCs from the cytotoxic ...
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
Suprachoroidal delivery of an integrin inhibitor suspension could provide targeting, compartmentalization and durability advantages over topical or intravitreal delivery, similar to what we have observed in other preclinical studies of small molecule suspensions, such as triamcinolone acetonide and ...
Manufactured by:ClearPoint Neuro, Inc. based inIrvine, CALIFORNIA (USA)
It has also been CE marked for use in Europe for the delivery of approved fluids into the brain or aspiration of CSF. It’s being utilized in approved clinical and preclinical studies for various research and drug trials. This device is not intended for implant and is intended for single patient use ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg dose in a lymphoma study and with a ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166, have led to complete regressions in models of breast and lung cancer at therapeutically relevant doses, and are well tolerated in non-human ...
Manufactured by:Actym Therapeutics based inBerkeley, CALIFORNIA (USA)
The company has developed an attenuated, microbial-based, technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident antigen-presenting cells. ...
Manufactured by:Galera Therapeutics, Inc. based inMalvern, PENNSYLVANIA (USA)
Avasopasem manganese (GC4419) is an investigational selective dismutase mimetic drug in development as a radioprotector in combination with radiation therapy (RT), with the goal to reduce side effects from radiation therapy. In preclinical studies, our selective dismutase mimetics significantly reduced immediate and long-term radiation damage to normal tissue in ...
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
We believe this broad VEGF blockade may have efficacy advantages over existing retinal therapies and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in preclinical studies in multiple species. With CLS-AX, ...